Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00212329 · ClinicalTrials.gov registry record
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
A clinical trial, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- 100
- Enrollment target
NCT00212329 is a clinical trial that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 100 participants.
The verdict
NCT00212329 has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
Type 1 diabetes is a condition that is caused in part by an abnormality of the immune system which occurs when T cells, which are part of the immune system, damage the insulin secreting cells (islet cells) in the pancreas. Although it is known that T cells are important mediators of the disease, progress in the development of reliable T cell assays has been modest. The purpose of this study is to learn which T cell assays are most reliable and reproducible so that the investigators can improve their understanding about how type 1 diabetes occurs.
Interventions
- PROCEDURE T Cell Proliferation and Autoreactivity Assays
- PROCEDURE Cellular Immunoblot Assays
- PROCEDURE Tetramer Studies
- PROCEDURE Cytokine ELISPOT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00212329
The ClinicalTrials.gov registry entry for NCT00212329 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which T Cell Proliferation and Autoreactivity Assays is the first listed.
NCT00212329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00212329 about?
NCT00212329 is a clinical study titled "T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus". Type 1 diabetes is a condition that is caused in part by an abnormality of the immune system which occurs when T cells, which are part of the immune system, damage the insulin secreting cells (islet cells) in the pancreas. Although it is known that T cells are important mediators of the disease, pro...
What is the current status of trial NCT00212329?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2005-09. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00212329?
The interventions under investigation include: T Cell Proliferation and Autoreactivity Assays (PROCEDURE), Cellular Immunoblot Assays (PROCEDURE), Tetramer Studies (PROCEDURE), Cytokine ELISPOT (PROCEDURE).
Who is sponsoring clinical trial NCT00212329?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.